Read our COVID-19 research and news.

Webinar Technology

Unraveling the link between the gut microbiome, human health, and disease

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Unraveling the link between the gut microbiome, human health, and disease

03 June 2020

12:00 p.m. ET

Register to watch recording

Speakers

As our knowledge and understanding of the microbiome has grown, so has the recognition that these microscopic hitchhikers play a critical role in human health as well as in disease. The relationship between the gut microbiota and conditions like nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) is an active area of research, with data hinting that the abundance of certain bacterial species, or an imbalance in the relative levels of different species, is linked to the incidence of these ailments. In regard to CVD, the hypothesis is that certain microbes regulate the level of plasma lipopolysaccharides, which in turn dials the immune response up or down, impacting atherosclerotic lesion formation. In NAFLD, multiple hits—for example overnutrition and gut microbiome dysbiosis—may influence the transition from NAFLD to inflammation-based liver disease. Additionally, the associations between bacterial genera and disease appear to vary across ethnicity/race.

This webinar will investigate how the makeup of the gut microbiome impacts NAFLD and CVD in particular, and human health in general, and how better understanding this impact might lead to the development of more effective therapies.

During the webinar, the speaker will:

  • Outline how changes in the abundance of certain bacterial species might create conditions that promote the occurrence of certain diseases
  • Explain specific pathways through which molecules secreted by the gut microbiome might impact disease
  • Describe how this data might inform the development of new and different therapies or modes of treatment
  • Answer audience questions during the live broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Tomoya Yamashita, M.D., Ph.D.

Kobe University Graduate School of Medicine
Kobe, Japan

Dr. Yamashita graduated with his M.D. from Kobe University in 1993, going on to complete his doctoral degree in 2000 at the same institution. He undertook his postdoctoral training at the University of California, San Diego before returning to Japan to join Kobe University Hospital, where he is currently an associate professor of medicine. Dr. Yamashita works as a cardiologist and as a basic researcher in cardiovascular medicine, with a focus on atherosclerosis and heart failure. More recently, he has become interested in the role that gut microbiota might play in cardiovascular disease, and in developing drugs based on the gut microbiome to treat these disorders.

Meredith Hullar, Ph.D.

Fred Hutchinson Cancer Research Center
Seattle, WA

Dr. Hullar currently holds a research faculty position as principle staff scientist at Fred Hutchinson Cancer Research Center in Seattle, Washington. Her research involves studies within large human population cohorts to assess the role of the microbiome and adiposity in disease risk, the prevalence and mechanisms of bacteria-associated malignancies such as colorectal cancer, and the role of the microbiome in cancer prevention through dietary interventions. Her Ph.D. studies were completed at Harvard University with Colleen M. Cavanaugh and followed by a postdoctoral fellowship at the University of Washington in the Civil and Environmental Engineering department with David A. Stahl. Dr. Hullar has shared her work through numerous national and international meetings and peer-reviewed publications as well as book chapters and invited talks.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here